Methamphetamine (Crystal Meth): Dependence, Withdrawal, and Recovery Support

Methamphetamine is behind most of the country's stimulant overdose deaths. In 2023, 34,855 overdose deaths in the United States involved "psychostimulants with abuse potential," the CDC's category for "drugs such as methamphetamine, amphetamine, and methylphenidate," and in 2024 the number was 28,722 (CDC, 2026). Within that category, the CDC says, "methamphetamine accounts for the majority of deaths" (CDC, 2025). Meth is hard to stop because the drug produces days of energy and confidence, and quitting produces the opposite, a crash that can last weeks. This page covers what meth is, whether stopping is dangerous, how withdrawal unfolds, what treatment works, and how support at home fits in.

What methamphetamine is and how it works

Methamphetamine is a Schedule II stimulant, a class the DEA defines by "a high potential for abuse, with use potentially leading to severe psychological or physical dependence" (DEA). Its one legal form, Desoxyn, is FDA-approved for attention deficit hyperactivity disorder, and its label opens with a boxed warning that it "has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction" (Desoxyn prescribing information, 2023).

The illicit drug comes as powder, pills, or the clear crystals the DEA describes as resembling "glass fragments" (DEA fact sheet). Street names include meth, crystal, ice, glass, shards, crank, speed, Tina, go-fast, chalk, and tweak (DEA). It is smoked, snorted, swallowed, or injected, and today's supply is unusually strong. The DEA reports that samples seized through 2024 "averaged 95 percent purity" and that methamphetamine "is often sold as fake pharmaceutical pills mimicking legitimate prescription pills (typically Adderall)" (DEA, 2025). A student who thinks she is buying Adderall may be taking meth.

Two facts matter for anyone trying to stop. First, it lasts. SAMHSA puts it plainly: "The half-life of a single dose of MA is about 10 hours," against "about 60 minutes" for cocaine (SAMHSA TIP 33, Chapter 2). The Desoxyn label reports a shorter figure for the tablet, "in the range of 4 to 5 hours" (Desoxyn label); either way, one dose lasts most of a day. Second, tolerance comes fast: "tolerance develops rapidly to the euphoric effects of stimulants and is the ostensible cause for most dose escalation" (TIP 33, Chapter 3).

Risky use, dependence, and addiction are not the same thing

People use these words interchangeably, and the confusion does damage. Dependence means the body has adapted, and the Desoxyn label lists what happens when the drug is removed: "Withdrawal signs and symptoms after abrupt discontinuation or dose reduction following prolonged use of CNS stimulants including DESOXYN include dysphoric mood; depression; fatigue; vivid, unpleasant dreams; insomnia or hypersomnia; increased appetite; and psychomotor retardation or agitation" (Desoxyn label). That is pharmacology, not character.

Risky use is any use of the illicit drug, because the dose and contents are unknown. A stimulant use disorder, what most people mean by addiction, is the pattern of continuing despite harm, and SAMHSA describes how quickly it forms: high-dose patterns "often lead to even more compulsive bingeing over a few hours to days that ceases only when the individual is totally exhausted or the stimulant supply runs out" (TIP 33, Chapter 3). In 2024, 2.4 million people aged 12 or older used methamphetamine in the past year (SAMHSA NSDUH, 2024). What we ask families is not "how much" but "what has it started to cost."

Signs methamphetamine has become a problem

The signs families describe to us most often look like this. Days awake, then a day or two of sleep that nothing interrupts. SAMHSA reports that meth binges run "from 3 to 15 days," far longer than cocaine (TIP 33, Chapter 3). Weight dropping without a diet. Repetitive, locked-in behavior, what SAMHSA calls "stereotyped activity," such as "vacuuming the same part of the floor over and over again, popping knuckles repeatedly, picking at scabs." Sores on the arms and face from the "sensation of insects creeping on or under the skin" (DEA). Suspicion that hardens into certainty: the neighbors are watching, the phone is tapped. Teeth breaking; in one group of people who used meth, "31% had six or more missing teeth, compared to 8.5% in the general population," driven by dry mouth, clenching, and sugary drinks (Newell et al., 2025). Any one of these is worth a conversation. Several together are worth a call.

Is stopping meth dangerous?

Rarely in the way alcohol or benzodiazepine withdrawal is dangerous, and seriously in a different way. For stimulants, SAMHSA states, "No consistent physiologic disruptions requiring gradual withdrawal have been observed" (TIP 33, Chapter 3). There is no taper to design; the medical emergencies with meth happen during use. The DEA warns that "High doses may result in death from stroke, heart attack, or multiple organ problems caused by overheating" (DEA fact sheet), the Desoxyn label describes "Life-threatening hyperthermia (temperatures greater than 104°F) and rhabdomyolysis" in overdose, and SAMHSA reports that "Cardiovascular disease is the third leading cause of death, behind overdose and accidents, among people who use MA" (TIP 33, Chapter 3).

The danger of stopping is psychiatric. SAMHSA's protocol says that "in the first 1-2 weeks of withdrawal from stimulants, some patients may experience suicidality and should be monitored appropriately" (TIP 33, Chapter 3), and its description of the crash is blunt: "While in this depressed state, the person has an increased risk of suicide" (TIP 33, Chapter 2). If someone coming off meth starts talking about not wanting to be here, call or text 988. The 988 Suicide and Crisis Lifeline is free, confidential, and "available 24/7/365" (988 Lifeline). Two more risks belong here. Psychosis does not always end when the drug does: SAMHSA notes that "Psychotic symptoms may sometimes persist for months or years after use has ceased" (TIP 33, Chapter 2). And people often reach for what SAMHSA calls "landing gear," meaning "alcohol, benzodiazepines, cannabis, or opioids, to induce and prolong sleep" (TIP 33, Chapter 3). With fentanyl in the supply, that is how a stimulant problem becomes an opioid death.

Methamphetamine withdrawal timeline

Everyone differs. How long and how heavily you used, and what else you take, change the shape. SAMHSA's summary is that "Symptoms begin 2 to 4 days after a person stops use and may persist for 2 to 4 weeks" (TIP 33, Chapter 3). This is the general pattern we see.

First 1 to 3 days: the crash

"Over the course of 1 to 14 days after last use, the person using MA experiences a drastic drop in mood and energy levels," SAMHSA writes, and then sleep "finally begins and may last more or less uninterrupted for several days" (TIP 33, Chapter 2). Expect enormous hunger on waking. Families often mistake this for the worst of it. It is the easiest part.

Days 3 to 10

The label's list arrives now: low mood, fatigue, vivid and unpleasant dreams, broken sleep, a big appetite, and either slowed movement or agitation. Cravings tend to be strongest here, and this is the window SAMHSA flags for suicidality. Nobody should spend this week alone with a phone full of old contacts.

Weeks 2 to 4

Sleep starts to normalize. Energy is still low and the world feels gray; SAMHSA notes that "Withdrawal from MA use can be protracted, lasting several weeks." Cravings shift from constant to situational: payday, a certain friend's name on the screen, the hour the shift used to end.

Months 2 and beyond

Most people feel like themselves again, but not all at once; SAMHSA reports that "Anhedonia and dysphoria can last for months in people who use MA" (TIP 33, Chapter 3). Anhedonia means ordinary pleasures do not register yet. It lifts, and a plan that expects months is more realistic than one that expects a month.

How treatment works

"There are no FDA-approved medications for managing stimulant use disorders" (SAMHSA TIP 33, Executive Summary). The treatments with evidence are behavioral, and one stands above the rest. SAMHSA states that "Ample research supports the use of CM as the primary psychosocial treatment for stimulant use disorders." Contingency management is simple: a person earns rewards, usually gift cards or vouchers, for stimulant-negative tests. SAMHSA describes it as "a well-known behavioral intervention designed to increase desired behaviors by providing immediate reinforcing consequences" with "by far the greatest amount of empirical support" among stimulant treatments (TIP 33, Chapter 4). Meth trains the brain on immediate reward; CM answers in the same language.

Cognitive behavioral therapy, the Matrix Model, and the community reinforcement approach round out the options; SAMHSA is candid that CBT alone has mixed results and that "CBT in combination with CM may be especially helpful" (TIP 33, Chapter 4).

The largest medication trial to date, ADAPT-2, combined injectable extended-release naltrexone (380 mg every three weeks) with extended-release bupropion (450 mg daily) in adults with moderate or severe methamphetamine use disorder. The weighted response rate, at least three of four meth-negative urine samples, was 13.6 percent with the combination versus 2.5 percent with placebo, a number needed to treat of 9 (Trivedi et al., NEJM, 2021). A real effect, and a modest one. A prescriber may offer it off-label; it is not a substitute for the behavioral work.

Methamphetamine with alcohol, opioids, or GHB

One number should change how everyone thinks about meth: in a CDC analysis of deaths from January 2021 through June 2024, "68.8% of methamphetamine-involved deaths" also involved opioids (CDC MMWR, 2025). SAMHSA explains the mechanism: fentanyl and its analogs "are rapid acting and are increasingly being taken in combination with cocaine or MA, by accident or on purpose" (TIP 33, Chapter 2). Sometimes the fentanyl is deliberate; sometimes it is in the bag. Keep naloxone in the house and understand its limit: "No specific antidotes or antagonists to stimulant overdose are available, unlike naloxone for opioids" (TIP 33, Chapter 3). It treats the opioid half of a mixed overdose and nothing else.

Stimulant-only deaths look different: the CDC found those decedents were older and "more frequently had a history of cardiovascular disease (38.7% versus 21.2%)" (CDC MMWR, 2025). Alcohol raises those stakes and masks how impaired a person is. GHB, common where meth is used socially, is a depressant whose high-dose effects the DEA lists as "Unconsciousness, seizures, slowed heart rate, greatly slowed breathing, lower body temperature, vomiting, nausea, coma, and death" (DEA GHB fact sheet). A stimulant on top hides the sedation until it wears off.

Drug testing for methamphetamine

Methamphetamine is caught by the amphetamines line on standard panels. On the federal oral fluid panel, "The initial test cutoff for amphetamines (i.e., amphetamine, methamphetamine, MDMA, and MDA) is 50 ng/mL, and the confirmatory test cutoff for each amphetamine analyte is 25 ng/mL" (Federal Register, 2019). Screens are not the last word: "Some over-the-counter (OTC) decongestants (e.g., pseudoephedrine) register a positive drug test result for amphetamine" and that phentermine "commonly yields a false-positive initial amphetamines test" (SAMHSA TAP 32, 2012).

The one that trips people up is the nasal inhaler. Some decongestant inhalers contain levmetamfetamine, the l-isomer, and it confirms as methamphetamine. In SAMHSA's medical review officer case studies, a donor who blamed an inhaler had a specimen that was "approximately 90 percent" d-methamphetamine and was reported positive, because if only the inhaler were responsible "the percentage of l-methamphetamine would have been greater than 80 percent" (SAMHSA MRO case studies, 2024). Illicit meth is the d-isomer; a chiral test settles it.

Saliva windows are less settled than people expect. SAMHSA's general guidance is that "drug testing of oral fluids detects drug use during the previous 24-48 hours, regardless of the route of administration" (SAMHSA TAP 32). After a multi-day binge the window can stretch beyond that, and urine windows are longer still. We would rather not quote one number, because it depends on dose, duration, and the lab's cutoff.

Our members use saliva-based screening that is assigned at random through the week. You do not choose whether you test; you choose who sees the results. For someone in recovery from meth that usually means a spouse, a parent, or a prescriber. We explain the details in our guide to how sobriety monitoring works.

How recovery from methamphetamine works with Accountable

We are not a detox and we do not prescribe. Psychosis, suicidality, or overheating is an emergency room, not a coaching call. What we provide is the long stretch after, at home, for as long as you need it.

1. Get the full picture

In the first sessions your coach maps what is going on: how long the runs last, how you use, whether there has been paranoia, what you use to come down, and whether opioids or GHB are in the picture. We ask about mood directly, because that is where the risk sits. If you need a prescriber for depression, sleep, or the bupropion and naltrexone combination, we help you find one, and with your permission we coordinate so everyone works from the same plan.

2. Build a plan that fits your life

A plan that only works if you move home and quit your job is a plan you will abandon. Your coach helps you plan around the real calendar: the payday that used to become a run, the friend who is also a dealer, the 3 a.m. when the old number is right there. Because contingency management is the best-supported treatment, we build in immediate, concrete recognition for negative tests rather than waiting for a milestone. Daily peer group meetings and a weekly family Zoom group give the people around you their own place to get support.

3. Weekly check-ins through the long stretch

The gray months of anhedonia are where people quietly give up. Your coach shows up every week, and the saliva screening turns "I think he's doing okay" into a shared record you control. When a return to use happens, we treat it as information. The plan changes and the support goes up, and because so many meth deaths involve fentanyl, we make sure naloxone is in the house. Every coach at Accountable has their own recovery behind them, and many have been through stimulants specifically.

Accountable is covered by a growing list of commercial health plans, with more added each month, and private-pay plans start at $375 per month. You can check your coverage in a few minutes or call the care team at (646) 450-7641. Families are welcome to make the first call; see our page for families.

Common questions

How long does meth stay in your system?

SAMHSA puts the half-life of a single dose at about 10 hours (TIP 33, Chapter 2), so most of one dose is gone within two to three days. Saliva testing generally detects use in the previous 24 to 48 hours (SAMHSA TAP 32); a multi-day binge extends that, and urine stays positive longer.

How long does meth withdrawal last?

The crash comes first, then symptoms that "begin 2 to 4 days after a person stops use and may persist for 2 to 4 weeks" (TIP 33, Chapter 3). Low mood and the inability to enjoy things "can last for months."

Is there a medication for meth addiction?

Not an approved one. "There are no FDA-approved medications for managing stimulant use disorders" (SAMHSA TIP 33). The naltrexone and bupropion combination helped 13.6 percent of participants versus 2.5 percent on placebo in a 2021 trial (Trivedi et al., 2021), and some prescribers offer it off-label.

Can meth cause permanent psychosis?

Usually paranoia and hallucinations fade with sleep and abstinence, but not always. SAMHSA reports that "Psychotic symptoms may sometimes persist for months or years after use has ceased" (TIP 33, Chapter 2), and the Desoxyn label notes that stimulants "may cause psychotic or manic symptoms" even in people with no prior history (Desoxyn label). Persistent symptoms need a psychiatrist.

What should I do if someone on meth is burning up, having a seizure, or will not wake up?

Call 911. SAMHSA lists "hyperpyrexia (excessively high fever), severe hypertension, convulsions, and cardiovascular collapse" as signals of "a life-threatening situation" (TIP 33, Chapter 3). Move them somewhere cool while you wait. If they are unresponsive or breathing slowly, give naloxone if you have it; most meth deaths involve opioids too (CDC MMWR, 2025), and it does no harm if they are not.

Sources

• Centers for Disease Control and Prevention, National Center for Health Statistics. Drug Overdose Deaths in the United States, 2023-2024. NCHS Data Brief No. 549, January 2026.

• Centers for Disease Control and Prevention. Stimulant Overdose. Overdose Prevention, reviewed July 17, 2025.

• Tanz LJ, Miller KD, Dinwiddie AT, et al. Drug Overdose Deaths Involving Stimulants: United States, January 2018-June 2024. MMWR Morbidity and Mortality Weekly Report, 2025;74(32), August 28, 2025.

• Drug Enforcement Administration. Methamphetamine drug fact sheet.

• Drug Enforcement Administration. Drug Scheduling.

• Drug Enforcement Administration. Methamphetamine, Get Smart About Drugs.

• Drug Enforcement Administration. 2025 National Drug Threat Assessment. May 2025.

• Drug Enforcement Administration. GHB (Gamma-Hydroxybutyric Acid) drug fact sheet.

• U.S. Food and Drug Administration. Desoxyn (methamphetamine hydrochloride tablets, USP) prescribing information, revised October 2023.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Executive Summary. Updated 2021, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Chapter 2: How Stimulants Affect the Brain and Behavior. Updated 2021, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Chapter 3: Medical Aspects of Stimulant Use Disorders. Updated 2021, NCBI Bookshelf.

• Substance Abuse and Mental Health Services Administration. TIP 33: Treatment for Stimulant Use Disorders, Chapter 4: Approaches to Treatment. Updated 2021, NCBI Bookshelf.

• Trivedi MH, Walker R, Ling W, et al. Bupropion and Naltrexone in Methamphetamine Use Disorder. New England Journal of Medicine. 2021;384(2):140-153.

• Substance Abuse and Mental Health Services Administration. Key Substance Use and Mental Health Indicators in the United States: Results from the 2024 National Survey on Drug Use and Health. 2025.

• Substance Abuse and Mental Health Services Administration. TAP 32: Clinical Drug Testing in Primary Care. Technical Assistance Publication Series, SMA12-4668, 2012.

• Substance Abuse and Mental Health Services Administration. 2024 Medical Review Officer (MRO) Case Studies - Oral Fluid. 2024.

• Department of Health and Human Services. Mandatory Guidelines for Federal Workplace Drug Testing Programs: Oral Fluid. Federal Register, October 25, 2019, effective January 1, 2020.

• Newell L-R, Fouillen K-J, Orliaguet M, Kichenin J, Boisramé S. Oral Health Effects of Ecstasy (MDMA) and Methamphetamine: A Narrative Review. Frontiers in Oral Health. 2025;6:1645445.

• 988 Suicide and Crisis Lifeline. 988lifeline.org.